Andrew DelaCourt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andrew DelaCourt has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Anand S. Mehta
Medical University of South Carolina
17 shared publications - Calvin R. K. Blaschke
Department of Cellular and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina 29425-2503, United States
17 shared publications - David Lewin
Medical University of South Carolina 7 Department of Pathology and Laboratory Medicine Charleston, South Carolina
17 shared publications - Kendell D. Peterson
Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina
17 shared publications - Lewis Rowland Roberts
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
17 shared publications - Mengjun Wang
Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina
17 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table ST2 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
Lists individual N-glycans, ALT (Alanine transaminase), AST (aspartate aminotransferase), ALK (Alkaline phosphatase), and AFP (Alpha-fetoprotein) of analysis to differentiate patients with iCCA from PSC. 1Possible biomarkers 2n: number of total patients 3distribution of iCCA (n=30) and PSC (n=17) patients. 4AUC (Area Under the Curve) 5CI (confidence interval) 6p value. Some iCCA patients were excluded from the analysis due to missing clinical information.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table ST2 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
Lists individual N-glycans, ALT (Alanine transaminase), AST (aspartate aminotransferase), ALK (Alkaline phosphatase), and AFP (Alpha-fetoprotein) of analysis to differentiate patients with iCCA from PSC. 1Possible biomarkers 2n: number of total patients 3distribution of iCCA (n=30) and PSC (n=17) patients. 4AUC (Area Under the Curve) 5CI (confidence interval) 6p value. Some iCCA patients were excluded from the analysis due to missing clinical information.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure SF1 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
Hematoxylin & Eosin (H&E) staining of A. Intrahepatic Cholangiocarcinoma (iCCA) tissue, 10x (right) and 40x (left) magnification images from respective areas of the tissue, and B. Hepatocellular Carcinoma (HCC) tissue, 10x magnification images from respective areas of the tissue. Tumor regions are outlined in red, normal areas are outlined in black and fibrotic regions are outlined in blue. C. TMA H&E staining with an outline that specifies the diagnosis for each core for TMA 1 (left) and TMA 2 (right). Mixed carcinoma: HCC and iCCA. Small (yellow) and large (purple) ducts classifications for each TMA.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure SF1 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
Hematoxylin & Eosin (H&E) staining of A. Intrahepatic Cholangiocarcinoma (iCCA) tissue, 10x (right) and 40x (left) magnification images from respective areas of the tissue, and B. Hepatocellular Carcinoma (HCC) tissue, 10x magnification images from respective areas of the tissue. Tumor regions are outlined in red, normal areas are outlined in black and fibrotic regions are outlined in blue. C. TMA H&E staining with an outline that specifies the diagnosis for each core for TMA 1 (left) and TMA 2 (right). Mixed carcinoma: HCC and iCCA. Small (yellow) and large (purple) ducts classifications for each TMA.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure SF1 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
Hematoxylin & Eosin (H&E) staining of A. Intrahepatic Cholangiocarcinoma (iCCA) tissue, 10x (right) and 40x (left) magnification images from respective areas of the tissue, and B. Hepatocellular Carcinoma (HCC) tissue, 10x magnification images from respective areas of the tissue. Tumor regions are outlined in red, normal areas are outlined in black and fibrotic regions are outlined in blue. C. TMA H&E staining with an outline that specifies the diagnosis for each core for TMA 1 (left) and TMA 2 (right). Mixed carcinoma: HCC and iCCA. Small (yellow) and large (purple) ducts classifications for each TMA.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure SF1 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
Hematoxylin & Eosin (H&E) staining of A. Intrahepatic Cholangiocarcinoma (iCCA) tissue, 10x (right) and 40x (left) magnification images from respective areas of the tissue, and B. Hepatocellular Carcinoma (HCC) tissue, 10x magnification images from respective areas of the tissue. Tumor regions are outlined in red, normal areas are outlined in black and fibrotic regions are outlined in blue. C. TMA H&E staining with an outline that specifies the diagnosis for each core for TMA 1 (left) and TMA 2 (right). Mixed carcinoma: HCC and iCCA. Small (yellow) and large (purple) ducts classifications for each TMA.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table ST2 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
Lists individual N-glycans, ALT (Alanine transaminase), AST (aspartate aminotransferase), ALK (Alkaline phosphatase), and AFP (Alpha-fetoprotein) of analysis to differentiate patients with iCCA from PSC. 1Possible biomarkers 2n: number of total patients 3distribution of iCCA (n=30) and PSC (n=17) patients. 4AUC (Area Under the Curve) 5CI (confidence interval) 6p value. Some iCCA patients were excluded from the analysis due to missing clinical information.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table ST2 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
Lists individual N-glycans, ALT (Alanine transaminase), AST (aspartate aminotransferase), ALK (Alkaline phosphatase), and AFP (Alpha-fetoprotein) of analysis to differentiate patients with iCCA from PSC. 1Possible biomarkers 2n: number of total patients 3distribution of iCCA (n=30) and PSC (n=17) patients. 4AUC (Area Under the Curve) 5CI (confidence interval) 6p value. Some iCCA patients were excluded from the analysis due to missing clinical information.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table ST1 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
Peak list of N-glycans detected in tissue (TMA) and serum samples.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table ST1 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
Peak list of N-glycans detected in tissue (TMA) and serum samples.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table ST1 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
Peak list of N-glycans detected in tissue (TMA) and serum samples.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table ST1 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
Peak list of N-glycans detected in tissue (TMA) and serum samples.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
There is an urgent need for the identification of reliable prognostic biomarkers for patients with intrahepatic cholangiocarcinoma (iCCA) and alterations in N-glycosylation have demonstrated an immense potential to be used as diagnostic strategies for many cancers, including hepatocellular carcinoma (HCC). N-glycosylation is one of the most common post-translational modifications known to be altered based on the status of the cell. N-glycan structures on glycoproteins can be modified based on the addition or removal of specific N-glycan residues, some of which have been linked to liver diseases. However, little is known concerning the N-glycan alterations that are associated with iCCA. We characterized the N-glycan modifications quantitatively and qualitatively in three cohorts, consisting of two tissue cohorts: a discovery cohort (n = 104 cases) and a validation cohort (n = 75), and one independent serum cohort consisting of patients with iCCA, HCC, or benign chronic liver disease (n = 67). N-glycan analysis in situ was correlated to tumor regions annotated on histopathology and revealed that bisected fucosylated N-glycan structures were specific to iCCA tumor regions. These same N-glycan modifications were significantly upregulated in iCCA tissue and serum relative to HCC and bile duct disease, including primary sclerosing cholangitis (PSC) (P < 0.0001). N-glycan modifications identified in iCCA tissue and serum were used to generate an algorithm that could be used as a biomarker of iCCA. We demonstrate that this biomarker algorithm quadrupled the sensitivity (at 90% specificity) of iCCA detection as compared with carbohydrate antigen 19-9, the current “gold standard” biomarker of CCA.Significance:This work elucidates the N-glycan alterations that occur directly in iCCA tissue and utilizes this information to discover serum biomarkers that can be used for the noninvasive detection of iCCA.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
There is an urgent need for the identification of reliable prognostic biomarkers for patients with intrahepatic cholangiocarcinoma (iCCA) and alterations in N-glycosylation have demonstrated an immense potential to be used as diagnostic strategies for many cancers, including hepatocellular carcinoma (HCC). N-glycosylation is one of the most common post-translational modifications known to be altered based on the status of the cell. N-glycan structures on glycoproteins can be modified based on the addition or removal of specific N-glycan residues, some of which have been linked to liver diseases. However, little is known concerning the N-glycan alterations that are associated with iCCA. We characterized the N-glycan modifications quantitatively and qualitatively in three cohorts, consisting of two tissue cohorts: a discovery cohort (n = 104 cases) and a validation cohort (n = 75), and one independent serum cohort consisting of patients with iCCA, HCC, or benign chronic liver disease (n = 67). N-glycan analysis in situ was correlated to tumor regions annotated on histopathology and revealed that bisected fucosylated N-glycan structures were specific to iCCA tumor regions. These same N-glycan modifications were significantly upregulated in iCCA tissue and serum relative to HCC and bile duct disease, including primary sclerosing cholangitis (PSC) (P < 0.0001). N-glycan modifications identified in iCCA tissue and serum were used to generate an algorithm that could be used as a biomarker of iCCA. We demonstrate that this biomarker algorithm quadrupled the sensitivity (at 90% specificity) of iCCA detection as compared with carbohydrate antigen 19-9, the current “gold standard” biomarker of CCA.Significance:This work elucidates the N-glycan alterations that occur directly in iCCA tissue and utilizes this information to discover serum biomarkers that can be used for the noninvasive detection of iCCA.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure SF5 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
Relative intensity quantification of all N-glycans identified in serum (left row) and tissue (right row) analysis. Red font labeling for N-glycans follows the same trend between serum and tissue.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure SF5 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
Relative intensity quantification of all N-glycans identified in serum (left row) and tissue (right row) analysis. Red font labeling for N-glycans follows the same trend between serum and tissue.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure SF3 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
A. Relative contribution of each serum-glycan (left) and TMA-glycan (right) in the first and second principal components. The size and color of the circle represent a higher contribution of the glycan to the respective Dim. (Dimension). B. Three N-glycans in TMA and serum were identified after optimization. C. Relative intensity quantification for both TMAs of the respective N-glycan based on small and large duct classification. D. Two common N-glycans were identified between datasets. LOOCV (Leave-One-Out Cross-Validation). AUC (Area Under the Curve). E. Quantification of the relative contribution of N-glycans (left), table of N-glycans, and proposed structure with importance values (top) when removing N-glycan at 1339 m/z from the analysis. F. ROC (Receiving Operator Characteristic) curve classification for serum (left) ROC curve LOOCV (right) of N-glycans in E. G. List combinations of N-glycan as possible biomarkers to differentiate iCCA from PSC. For N-glycans, red triangle, fucose; blue square, N-acetylglucosamine; green circles, mannose; yellow circles, galactose.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure SF3 from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
A. Relative contribution of each serum-glycan (left) and TMA-glycan (right) in the first and second principal components. The size and color of the circle represent a higher contribution of the glycan to the respective Dim. (Dimension). B. Three N-glycans in TMA and serum were identified after optimization. C. Relative intensity quantification for both TMAs of the respective N-glycan based on small and large duct classification. D. Two common N-glycans were identified between datasets. LOOCV (Leave-One-Out Cross-Validation). AUC (Area Under the Curve). E. Quantification of the relative contribution of N-glycans (left), table of N-glycans, and proposed structure with importance values (top) when removing N-glycan at 1339 m/z from the analysis. F. ROC (Receiving Operator Characteristic) curve classification for serum (left) ROC curve LOOCV (right) of N-glycans in E. G. List combinations of N-glycan as possible biomarkers to differentiate iCCA from PSC. For N-glycans, red triangle, fucose; blue square, N-acetylglucosamine; green circles, mannose; yellow circles, galactose.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
There is an urgent need for the identification of reliable prognostic biomarkers for patients with intrahepatic cholangiocarcinoma (iCCA) and alterations in N-glycosylation have demonstrated an immense potential to be used as diagnostic strategies for many cancers, including hepatocellular carcinoma (HCC). N-glycosylation is one of the most common post-translational modifications known to be altered based on the status of the cell. N-glycan structures on glycoproteins can be modified based on the addition or removal of specific N-glycan residues, some of which have been linked to liver diseases. However, little is known concerning the N-glycan alterations that are associated with iCCA. We characterized the N-glycan modifications quantitatively and qualitatively in three cohorts, consisting of two tissue cohorts: a discovery cohort (n = 104 cases) and a validation cohort (n = 75), and one independent serum cohort consisting of patients with iCCA, HCC, or benign chronic liver disease (n = 67). N-glycan analysis in situ was correlated to tumor regions annotated on histopathology and revealed that bisected fucosylated N-glycan structures were specific to iCCA tumor regions. These same N-glycan modifications were significantly upregulated in iCCA tissue and serum relative to HCC and bile duct disease, including primary sclerosing cholangitis (PSC) (P < 0.0001). N-glycan modifications identified in iCCA tissue and serum were used to generate an algorithm that could be used as a biomarker of iCCA. We demonstrate that this biomarker algorithm quadrupled the sensitivity (at 90% specificity) of iCCA detection as compared with carbohydrate antigen 19-9, the current “gold standard” biomarker of CCA.Significance:This work elucidates the N-glycan alterations that occur directly in iCCA tissue and utilizes this information to discover serum biomarkers that can be used for the noninvasive detection of iCCA.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
There is an urgent need for the identification of reliable prognostic biomarkers for patients with intrahepatic cholangiocarcinoma (iCCA) and alterations in N-glycosylation have demonstrated an immense potential to be used as diagnostic strategies for many cancers, including hepatocellular carcinoma (HCC). N-glycosylation is one of the most common post-translational modifications known to be altered based on the status of the cell. N-glycan structures on glycoproteins can be modified based on the addition or removal of specific N-glycan residues, some of which have been linked to liver diseases. However, little is known concerning the N-glycan alterations that are associated with iCCA. We characterized the N-glycan modifications quantitatively and qualitatively in three cohorts, consisting of two tissue cohorts: a discovery cohort (n = 104 cases) and a validation cohort (n = 75), and one independent serum cohort consisting of patients with iCCA, HCC, or benign chronic liver disease (n = 67). N-glycan analysis in situ was correlated to tumor regions annotated on histopathology and revealed that bisected fucosylated N-glycan structures were specific to iCCA tumor regions. These same N-glycan modifications were significantly upregulated in iCCA tissue and serum relative to HCC and bile duct disease, including primary sclerosing cholangitis (PSC) (P < 0.0001). N-glycan modifications identified in iCCA tissue and serum were used to generate an algorithm that could be used as a biomarker of iCCA. We demonstrate that this biomarker algorithm quadrupled the sensitivity (at 90% specificity) of iCCA detection as compared with carbohydrate antigen 19-9, the current “gold standard” biomarker of CCA.Significance:This work elucidates the N-glycan alterations that occur directly in iCCA tissue and utilizes this information to discover serum biomarkers that can be used for the noninvasive detection of iCCA.